Per Borghammer

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/665840/publications.pdf

Version: 2024-02-01

76326 76900 6,541 137 40 74 citations h-index g-index papers 140 140 140 7020 times ranked docs citations citing authors all docs

#	Article	IF	Citations
1	Passive Immunization in Alpha-Synuclein Preclinical Animal Models. Biomolecules, 2022, 12, 168.	4.0	13
2	Cholinergic system changes in Parkinson's disease: emerging therapeutic approaches. Lancet Neurology, The, 2022, 21, 381-392.	10.2	70
3	In vivo vesicular acetylcholine transporter density in human peripheral organs: an [18F]FEOBV PET/CT study. EJNMMI Research, 2022, 12, 17.	2.5	6
4	Alpha-Synuclein Strain Variability in Body-First and Brain-First Synucleinopathies. Frontiers in Aging Neuroscience, 2022, 14, .	3.4	10
5	Brain atrophy in prodromal synucleinopathy is shaped by structural connectivity and gene expression. Brain, 2022, 145, 3162-3178.	7.6	13
6	Intestinal Transit in Early Moderate Parkinson's Disease Correlates with Probable RBD: Subclinical Esophageal Dysmotility Does Not Correlate. Parkinson's Disease, 2022, 2022, 1-8.	1.1	0
7	Imaging progressive peripheral and central dysfunction in isolated REM sleep behaviour disorder after 3 years of follow-up. Parkinsonism and Related Disorders, 2022, 101, 99-104.	2.2	5
8	Healthy brain aging assessed with [18F]FDG and [11C]UCB-J PET. Nuclear Medicine and Biology, 2022, 112-113, 52-58.	0.6	9
9	Assessing autonomic dysfunction with functional imaging in Parkinson's disease. International Review of Movement Disorders, 2021, , 91-118.	0.1	0
10	Microsleep disturbances are associated with noradrenergic dysfunction in Parkinson's disease. Sleep, 2021, 44, .	1.1	17
11	Cognitive impairment in Parkinson's disease is associated with Default Mode Network subsystem connectivity and cerebrospinal fluid Al². Parkinsonism and Related Disorders, 2021, 83, 71-78.	2.2	20
12	Assessment of Gastrointestinal Autonomic Dysfunction: Present and Future Perspectives. Journal of Clinical Medicine, 2021, 10, 1392.	2.4	14
13	The Logic and Pitfalls of Parkinson's as Brain―Versus Bodyâ€First Subtypes. Movement Disorders, 2021, 36, 785-786.	3.9	6
14	Monocyte markers correlate with immune and neuronal brain changes in REM sleep behavior disorder. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	35
15	The α-Synuclein Origin and Connectome Model (SOC Model) of Parkinson's Disease: Explaining Motor Asymmetry, Non-Motor Phenotypes, and Cognitive Decline. Journal of Parkinson's Disease, 2021, 11, 455-474.	2.8	81
16	Ageing promotes pathological alpha-synuclein propagation and autonomic dysfunction in wild-type rats. Brain, 2021, 144, 1853-1868.	7.6	73
17	Reduced Synaptic Density in Patients with Lewy Body Dementia: An [<scp>¹¹C</scp>] <scp>UCB†PET</scp> Imaging Study. Movement Disorders, 2021, 36, 2057-2065.	3.9	39
18	Prodromal Parkinson disease subtypes â€" key to understanding heterogeneity. Nature Reviews Neurology, 2021, 17, 349-361.	10.1	171

#	Article	IF	CITATIONS
19	Asymmetric Distribution of Dopamine Transporters in Premorbid Corticobasal Syndrome—A Case Report. Movement Disorders Clinical Practice, 2021, 8, 607-609.	1.5	0
20	Impaired cerebral microcirculation in isolated REM sleep behaviour disorder. Brain, 2021, 144, 1498-1508.	7.6	6
21	Preserved noradrenergic function in Parkinson's disease patients with rest tremor. Neurobiology of Disease, 2021, 152, 105295.	4.4	15
22	Fasting gallbladder volume is increased in patients with Parkinson's disease. Parkinsonism and Related Disorders, 2021, 87, 56-60.	2.2	3
23	Vagus Nerve Cross-Sectional Area in Patients With Parkinson's Disease—An Ultrasound Case-Control Study. Frontiers in Neurology, 2021, 12, 681413.	2.4	12
24	Radionuclide Imaging of the Gut–Brain Axis in Parkinson Disease. Journal of Nuclear Medicine, 2021, 62, 1504-1505.	5.0	1
25	Gastric Emptying Time and Volume of the Small Intestine as Objective Markers in Patients With Symptoms of Diabetic Enteropathy. Journal of Neurogastroenterology and Motility, 2021, 27, 390-399.	2.4	7
26	Cortical Activity During an Attack of Ménière's Disease—A Case Report. Frontiers in Neurology, 2021, 12, 669390.	2.4	1
27	Asymmetric Dopaminergic Dysfunction in Brain-First versus Body-First Parkinson's Disease Subtypes. Journal of Parkinson's Disease, 2021, 11, 1677-1687.	2.8	34
28	Regional locus coeruleus degeneration is uncoupled from noradrenergic terminal loss in Parkinson's disease. Brain, 2021, 144, 2732-2744.	7.6	57
29	Constipation is Associated with Development of Cognitive Impairment in de novo Parkinson's Disease: A Longitudinal Analysis of Two International Cohorts. Journal of Parkinson's Disease, 2021, 11, 1209-1219.	2.8	29
30	Gastrointestinal Dysfunction in Parkinson's Disease. Journal of Clinical Medicine, 2021, 10, 493.	2.4	37
31	Long-term Risk of Parkinson Disease Following Influenza and Other Infections. JAMA Neurology, 2021, 78, 1461.	9.0	45
32	Neuropathological evidence of body-first vs. brain-first Lewy body disease. Neurobiology of Disease, 2021, 161, 105557.	4.4	72
33	Enteric cholinergic neuropathy in patients with diabetes: Nonâ€invasive assessment with positron emission tomography. Neurogastroenterology and Motility, 2020, 32, e13731.	3.0	8
34	Normative values for regionâ€specific colonic and gastrointestinal transit times in 111 healthy volunteers using the 3Dâ€Transit electromagnet tracking system: Influence of age, gender, and body mass index. Neurogastroenterology and Motility, 2020, 32, e13734.	3.0	45
35	In vivo positron emission tomography imaging of decreased parasympathetic innervation in the gut of vagotomized patients. Neurogastroenterology and Motility, 2020, 32, e13759.	3.0	7
36	Positron emission tomography visualized stimulation of the vestibular organ is localized in Heschl's gyrus. Human Brain Mapping, 2020, 41, 185-193.	3.6	9

3

#	Article	IF	CITATIONS
37	Tau Tangles in Parkinson's Disease: A 2-Year Follow-Up Flortaucipir PET Study. Journal of Parkinson's Disease, 2020, 10, 161-171.	2.8	10
38	Colonic motility in patients with type 1 diabetes and gastrointestinal symptoms. Neurogastroenterology and Motility, 2020, 32, e13948.	3.0	14
39	Skin Temperature in Parkinson's Disease Measured by Infrared Thermography. Parkinson's Disease, 2020, 2020, 1-7.	1.1	9
40	Cortical cholinergic dysfunction correlates with microglial activation in the substantia innominata in REM sleep behavior disorder. Parkinsonism and Related Disorders, 2020, 81, 89-93.	2.2	14
41	Absent 18F-FDG Uptake in the Brain—Unsuspected Brain Death. Clinical Nuclear Medicine, 2020, 45, e433-e434.	1.3	1
42	Brain-first versus body-first Parkinson's disease: a multimodalÂimaging case-control study. Brain, 2020, 143, 3077-3088.	7.6	398
43	A Screening-Based Method for Identifying Patients with REM Sleep Behaviour Disorder in a Danish Community Setting. Journal of Parkinson's Disease, 2020, 10, 1249-1253.	2.8	2
44	Altered sensorimotor cortex noradrenergic function in idiopathic REM sleep behaviour disorder – A PET study. Parkinsonism and Related Disorders, 2020, 75, 63-69.	2.2	27
45	Normative values for gastric motility assessed with the 3Dâ€transit electromagnetic tracking system. Neurogastroenterology and Motility, 2020, 32, e13829.	3.0	7
46	PET Visualized Stimulation of the Vestibular Organ in Menière's Disease. Frontiers in Neurology, 2020, 11, 11.	2.4	19
47	Applied strategy in the Iowa Gambling Task: Comparison of individuals with Parkinson's disease to healthy controls. Journal of Clinical and Experimental Neuropsychology, 2020, 42, 425-435.	1.3	3
48	Imaging dopamine function and microglia in asymptomatic LRRK2 mutation carriers. Journal of Neurology, 2020, 267, 2296-2300.	3.6	18
49	Objective intestinal function in patients with idiopathic REM sleep behavior disorder. Parkinsonism and Related Disorders, 2019, 58, 28-34.	2.2	18
50	Evidence for bidirectional and trans-synaptic parasympathetic and sympathetic propagation of alpha-synuclein in rats. Acta Neuropathologica, 2019, 138, 535-550.	7.7	210
51	Brain-First versus Gut-First Parkinson's Disease: A Hypothesis. Journal of Parkinson's Disease, 2019, 9, S281-S295.	2.8	201
52	Cardiac ¹¹ C-Donepezil Binding Increases With Age in Healthy Humans: Potentially Signifying Sigma-1 Receptor Upregulation. Journal of Cardiovascular Pharmacology and Therapeutics, 2019, 24, 365-370.	2.0	7
53	18F-FACBC PET/MRI in Diagnostic Assessment and Neurosurgery of Gliomas. Clinical Nuclear Medicine, 2019, 44, 550-559.	1.3	23
54	18F-Fluciclovine PET/CT in Suspected Residual or Recurrent High-Grade Glioma. Clinical Nuclear Medicine, 2019, 44, 605-611.	1.3	30

#	Article	IF	CITATIONS
55	The relationship between tumor aggressiveness and cholinergic PET imaging in prostate cancer tissue. A proof-of-concept study. American Journal of Nuclear Medicine and Molecular Imaging, 2019, 9, 185-192.	1.0	4
56	Acetylcholinesterase-associated inflammation in patients with giant cell arteritis. Evaluation by histology and 11C-donepezil PET/CT. Clinical and Experimental Rheumatology, 2019, 37 Suppl 117, 20-25.	0.8	0
57	Observations on muscle activity in REM sleep behavior disorder assessed with a semi-automated scoring algorithm. Clinical Neurophysiology, 2018, 129, 541-547.	1.5	11
58	Evaluation of the noradrenergic system in Parkinson's disease: an 11C-MeNER PET and neuromelanin MRI study. Brain, 2018, 141, 496-504.	7.6	135
59	Extrastriatal monoaminergic dysfunction and enhanced microglial activation in idiopathic rapid eye movement sleep behaviour disorder. Neurobiology of Disease, 2018, 115, 9-16.	4.4	35
60	Noradrenergic Deficits in Parkinson Disease Imaged with ¹¹ C-MeNER. Journal of Nuclear Medicine, 2018, 59, 659-664.	5.0	40
61	How does parkinson's disease begin? Perspectives on neuroanatomical pathways, prions, and histology. Movement Disorders, 2018, 33, 48-57.	3.9	114
62	Tonsillectomy and risk of Parkinson's disease: A danish nationwide populationâ€based cohort study. Movement Disorders, 2018, 33, 321-324.	3.9	6
63	MAO-B Inhibitors Do Not Block In Vivo Flortaucipir([18F]-AV-1451) Binding. Molecular Imaging and Biology, 2018, 20, 356-360.	2.6	45
64	The Gut and Parkinson's Disease: Hype or Hope?. Journal of Parkinson's Disease, 2018, 8, S31-S39.	2.8	70
65	Evaluation of Active Brown Adipose Tissue by the Use of Hyperpolarized [1-13C]Pyruvate MRI in Mice. International Journal of Molecular Sciences, 2018, 19, 2597.	4.1	11
66	Imaging the Autonomic Nervous System in Parkinson's Disease. Current Neurology and Neuroscience Reports, 2018, 18, 79.	4.2	14
67	The Effect of 40-Hz Light Therapy on Amyloid Load in Patients with Prodromal and Clinical Alzheimer's Disease. International Journal of Alzheimer's Disease, 2018, 2018, 1-5.	2.0	28
68	Molecular Imaging of the Noradrenergic System in Idiopathic Parkinson's Disease. International Review of Neurobiology, 2018, 141, 251-274.	2.0	13
69	Is constipation in Parkinson's disease caused by gut or brain pathology?. Parkinsonism and Related Disorders, 2018, 55, 6-7.	2.2	15
70	Preclinical evaluation of potential infectionâ€imaging probe [⁶⁸ Ga] <scp>Gaâ€DOTAâ€Kâ€A9</scp> in sterile and infectious inflammation. Journal of Labelled Compounds and Radiopharmaceuticals, 2018, 61, 780-795.	1.0	8
71	Decreased noradrenaline transporter density in the motor cortex of Parkinson's disease patients. Movement Disorders, 2018, 33, 1006-1010.	3.9	33
72	In-vivo staging of pathology in REM sleep behaviour disorder: a multimodality imaging case-control study. Lancet Neurology, The, 2018, 17, 618-628.	10.2	228

#	Article	IF	Citations
73	Gastric emptying in Parkinson's disease – A mini-review. Parkinsonism and Related Disorders, 2018, 55, 18-25.	2.2	36
74	Does inflammation precede tau aggregation in early Alzheimer's disease? A PET study. Neurobiology of Disease, 2018, 117, 211-216.	4.4	46
75	Gastrointestinal transit time and heart rate variability in patients with mild acquired brain injury. Peerl, 2018, 6, e4912.	2.0	2
76	Non-invasive quantification of tumor blood flow in prostate cancer using O-HO PET/CT. American Journal of Nuclear Medicine and Molecular Imaging, 2018, 8, 292-302.	1.0	7
77	Decreased intestinal acetylcholinesterase in early Parkinson disease. Neurology, 2017, 88, 775-781.	1.1	75
78	In Vivo cortical tau in Parkinson's disease using 18F-AV-1451 positron emission tomography. Movement Disorders, 2017, 32, 922-927.	3.9	47
79	Objective Colonic Dysfunction is Far more Prevalent than Subjective Constipation in Parkinson's Disease: A Colon Transit and Volume Study. Journal of Parkinson's Disease, 2017, 7, 359-367.	2.8	92
80	Functional image-guided dose escalation in gliomas using of state-of-the-art photon vs. proton therapy. Acta Oncol \tilde{A}^3 gica, 2017, 56, 826-831.	1.8	4
81	Imaging Parkinson's disease below the neck. Npj Parkinson's Disease, 2017, 3, 15.	5.3	19
82	Preventing Parkinson disease by vagotomy. Neurology, 2017, 88, 1982-1983.	1.1	9
83	Brain inflammation accompanies amyloid in the majority of mild cognitive impairment cases due to Alzheimer's disease. Brain, 2017, 140, 2002-2011.	7.6	147
84	Pancreatic Polypeptide in Parkinson's Disease: A Potential Marker of Parasympathetic Denervation. Journal of Parkinson's Disease, 2017, 7, 645-652.	2.8	6
85	Gastrointestinal Transit Time in Parkinson's Disease Using a Magnetic Tracking System. Journal of Parkinson's Disease, 2017, 7, 471-479.	2.8	46
86	Multimodal 18 F-Fluciclovine PET/MRI and Ultrasound-Guided Neurosurgery of an Anaplastic Oligodendroglioma. World Neurosurgery, 2017, 108, 989.e1-989.e8.	1.3	12
87	Reply to the letter to the Editor: Comment to Barichella and colleagues. Movement Disorders, 2017, 32, 631-631.	3.9	0
88	Assessment of neuroinflammation in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a case-control study. Lancet Neurology, The, 2017, 16, 789-796.	10.2	155
89	Constipation in parkinson's disease: Subjective symptoms, objective markers, and new perspectives. Movement Disorders, 2017, 32, 94-105.	3.9	127
90	Cholinergic PET imaging in infections and inflammation using 11C-donepezil and 18F-FEOBV. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 449-458.	6.4	14

#	Article	IF	CITATIONS
91	Sex differences of human cortical blood flow and energy metabolism. Journal of Cerebral Blood Flow and Metabolism, 2017, 37, 2433-2440.	4.3	83
92	Kinetic Modelling of Infection Tracers [¹⁸ F]FDG, [⁶⁸ Ga]Ga-Citrate, [¹¹ C]Methionine, and [¹¹ C]Donepezil in a Porcine Osteomyelitis Model. Contrast Media and Molecular Imaging, 2017, 2017, 1-18.	0.8	11
93	Pathological αâ€synuclein in gastrointestinal tissues from prodromal <scp>P</scp> arkinson disease patients. Annals of Neurology, 2016, 79, 940-949.	5.3	314
94	Imaging Systemic Dysfunction in Parkinson's Disease. Current Neurology and Neuroscience Reports, 2016, 16, 51.	4.2	23
95	<i>In vivo</i> imaging of neuromelanin in Parkinson's disease using ¹⁸ F-AV-1451 PET. Brain, 2016, 139, 2039-2049.	7.6	113
96	Vagotomy and subsequent development of diabetes – A nested case–control study. Metabolism: Clinical and Experimental, 2016, 65, 954-960.	3.4	6
97	Appendectomy and risk of Parkinson's disease: A nationwide cohort study with more than 10 years of follow-up. Movement Disorders, 2016, 31, 1918-1922.	3.9	58
98	A dual tracer 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT pilot study for detection of cardiac sarcoidosis. EJNMMI Research, 2016, 6, 52.	2.5	112
99	Constipation and risk of Parkinson's disease: A Danish population-based cohort study. Parkinsonism and Related Disorders, 2016, 28, 18-22.	2.2	35
100	Colonic volume and gastrointestinal symptoms in Parkinson's disease. Parkinsonism and Related Disorders, 2016, 22, e46.	2.2	3
101	Molecular imaging of cholinergic processes in prostate cancer using 11C-donepezil and 18F-FEOBV. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 906-910.	6.4	2
102	Utility of C-methionine and C-donepezil for imaging of induced osteomyelitis in a juvenile porcine model: comparison to autologous In-labelled leukocytes, Tc-DPD, and F-FDG. American Journal of Nuclear Medicine and Molecular Imaging, 2016, 6, 286-300.	1.0	11
103	Vagotomy and subsequent risk of <scp>P</scp> arkinson's disease. Annals of Neurology, 2015, 78, 522-529.	5.3	625
104	Does vagotomy reduce the risk of Parkinson's disease: The authors reply. Annals of Neurology, 2015, 78, 1012-1013.	5. 3	13
105	Reply. Annals of Neurology, 2015, 78, 835-835.	5.3	2
106	Olfactory function in Parkinson's Disease - effects of training. Acta Neurologica Scandinavica, 2015, 132, 395-400.	2.1	24
107	Accuracy of 18F-FDG PET-CT in triaging lung cancer patients with suspected brain metastases for MRI. Nuclear Medicine Communications, 2015, 36, 1084-1090.	1.1	17
108	Salivary Acetylcholinesterase Activity Is Increased in Parkinson's Disease: A Potential Marker of Parasympathetic Dysfunction. Parkinson's Disease, 2015, 2015, 1-7.	1.1	28

#	Article	IF	Citations
109	Imaging acetylcholinesterase density in peripheral organs in Parkinson's disease with 11C-donepezil PET. Brain, 2015, 138, 653-663.	7.6	135
110	Clinical correlates of raphe serotonergic dysfunction in early Parkinson's disease. Brain, 2015, 138, 2964-2973.	7.6	164
111	Spatial distribution of malignant tissue in gliomas: correlations of $\langle \sup 11 \langle \sup \rangle C$ -L-methionine positron emission tomography and perfusion- and diffusion-weighted magnetic resonance imaging. Acta Radiologica, 2015, 56, 1135-1144.	1.1	19
112	Pseudoprogression after proton radiotherapy for pediatric low grade glioma. Acta $Oncol\tilde{A}^3$ gica, 2015, 54, 1701-1702.	1.8	9
113	In Vivo Imaging of Human Acetylcholinesterase Density in Peripheral Organs Using $\langle \sup 11 \rangle$ sup>C-Donepezil: Dosimetry, Biodistribution, and Kinetic Analyses. Journal of Nuclear Medicine, 2014, 55, 1818-1824.	5.0	40
114	Combined DaT imaging and olfactory testing for differentiating parkinsonian disorders. International Journal of Clinical Practice, 2014, 68, 1345-1351.	1.7	12
115	False-Positive 123I-FP-CIT Scintigraphy and Suggested Dopamine Transporter Upregulation Due to Chronic Modafinil Treatment. Clinical Nuclear Medicine, 2014, 39, e87-e88.	1.3	6
116	Brain Energy Metabolism and Blood Flow Differences in Healthy Aging. Journal of Cerebral Blood Flow and Metabolism, 2012, 32, 1177-1187.	4.3	145
117	Cerebral oxygen metabolism in patients with early Parkinson's disease. Journal of the Neurological Sciences, 2012, 313, 123-128.	0.6	26
118	Glucose metabolism in small subcortical structures in Parkinson's disease. Acta Neurologica Scandinavica, 2012, 125, 303-310.	2.1	36
119	Clinical heterogeneity in Parkinson's disease revisited: a latent profile analysis. Acta Neurologica Scandinavica, 2012, 125, 311-318.	2.1	20
120	Perfusion and metabolism imaging studies in Parkinson's disease. Danish Medical Journal, 2012, 59, 84466.	0.5	24
121	Molecular Imaging and the Neuropathologies of Parkinson's Disease. Current Topics in Behavioral Neurosciences, 2011, 11, 117-148.	1.7	14
122	Odor identification deficits identify Parkinson's disease patients with poor cognitive performance. Movement Disorders, 2011, 26, 2045-2050.	3.9	38
123	Variable ATP Yields and Uncoupling of Oxygen Consumption in Human Brain. Advances in Experimental Medicine and Biology, 2011, 701, 243-248.	1.6	5
124	The Parkinsonian Personality and Concomitant Depression. Journal of Neuropsychiatry and Clinical Neurosciences, 2011, 23, 48-55.	1.8	14
125	The parkinsonian personality and concomitant depression. Journal of Neuropsychiatry and Clinical Neurosciences, 2011, 23, 48-55.	1.8	5
126	Cortical hypometabolism and hypoperfusion in Parkinson's disease is extensive: probably even at early disease stages. Brain Structure and Function, 2010, 214, 303-317.	2.3	140

#	Article	IF	CITATIONS
127	A deformationâ€based morphometry study of patients with earlyâ€stage Parkinson's disease. European Journal of Neurology, 2010, 17, 314-320.	3.3	80
128	Partial volume correction using cortical surfaces. , 2010, , .		0
129	Age-dependent decline of steady state dopamine storage capacity of human brain: An FDOPA PET study. Neurobiology of Aging, 2010, 31, 447-463.	3.1	47
130	Low Cerebral Oxygen Consumption and Blood Flow in Patients With Cirrhosis and an Acute Episode of Hepatic Encephalopathy. Gastroenterology, 2009, 136, 863-871.	1.3	102
131	Artefactual subcortical hyperperfusion in PET studies normalized to global mean: Lessons from Parkinson's disease. Neurolmage, 2009, 45, 249-257.	4.2	78
132	Data-driven intensity normalization of PET group comparison studies is superior to global mean normalization. NeuroImage, 2009, 46, 981-988.	4.2	56
133	Subcortical elevation of metabolism in Parkinson's disease â€" A critical reappraisal in the context of global mean normalization. NeuroImage, 2009, 47, 1514-1521.	4.2	50
134	Effect of memantine on CBF and CMRO ₂ in patients with early Parkinson's disease. Acta Neurologica Scandinavica, 2008, 117, 317-323.	2.1	18
135	Improvement of brain tissue oxygenation by inhalation of carbogen. Neuroscience, 2008, 156, 932-938.	2.3	51
136	Normalization in PET group comparison studiesâ€"The importance of a valid reference region. NeuroImage, 2008, 40, 529-540.	4.2	87
137	Fluorodopa F 18 Positron Emission Tomography and the Progression of Parkinson Disease. Archives of Neurology, 2005, 62, 1480.	4.5	5